BAY2586116
/ Bayer
- LARVOL DELTA
Home
Next
Prev
1 to 15
Of
15
Go to page
1
January 12, 2024
A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: A randomized, blinded, trial.
(PubMed, Am J Physiol Heart Circ Physiol)
- P2 | "In conclusion, BAY2586116 reduces OSA severity during sleep in people who demonstrate physiological improvement in upper airway collapsibility. These findings highlight the therapeutic potential for this novel pharmacotherapy target in selected individuals."
Journal • Anesthesia • CNS Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
February 15, 2023
BAY2586116 Nasal Spray and OSA Severity
(clinicaltrials.gov)
- P1 | N=10 | Completed | Sponsor: Flinders University | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Dec 2022
Trial completion • Trial completion date • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
November 27, 2022
Topical K channel blockage improves pharyngeal collapsibility: A translational, placebo-controlled trial.
(PubMed, Chest)
- P2 | "Acute topical application of BAY2586116 improves upper-airway collapsibility in anesthetized pigs and sleeping humans with OSA. These novel physiology findings highlight the therapeutic potential to target K channel mechanisms to treat OSA."
Journal • Anesthesia • CNS Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
September 02, 2022
BAY2586116 Nasal Spray and OSA Severity
(clinicaltrials.gov)
- P1 | N=8 | Recruiting | Sponsor: Flinders University
New P1 trial • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
November 17, 2021
SPRAY-SMART: A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea
(clinicaltrials.gov)
- P2; N=93; Completed; Sponsor: Bayer; Active, not recruiting ➔ Completed
Clinical • Trial completion • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
September 08, 2021
A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose
(clinicaltrials.gov)
- P1; N=36; Completed; Sponsor: Bayer; Recruiting ➔ Completed
Clinical • Trial completion • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder
August 17, 2021
SPRAY-SMART: A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea
(clinicaltrials.gov)
- P2; N=93; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting; N=160 ➔ 93
Clinical • Enrollment change • Enrollment closed • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
July 12, 2021
KOALA: Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration
(clinicaltrials.gov)
- P2; N=14; Completed; Sponsor: Bayer; Active, not recruiting ➔ Completed
Clinical • Trial completion • CNS Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
June 07, 2021
A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose
(clinicaltrials.gov)
- P1; N=36; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder
May 04, 2021
A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose
(clinicaltrials.gov)
- P1; N=36; Not yet recruiting; Sponsor: Bayer
Clinical • New P1 trial • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder
March 15, 2021
SPRAY-SMART: A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea
(clinicaltrials.gov)
- P2; N=160; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
January 19, 2021
SPRAY-SMART: A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea
(clinicaltrials.gov)
- P2; N=160; Not yet recruiting; Sponsor: Bayer
Clinical • New P2 trial • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
November 19, 2020
KOALA: Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration
(clinicaltrials.gov)
- P2; N=14; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2021 ➔ May 2021; Trial primary completion date: Nov 2020 ➔ Mar 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder
February 27, 2020
KOALA: Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration
(clinicaltrials.gov)
- P2; N=12; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
January 22, 2020
KOALA: Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration
(clinicaltrials.gov)
- P2; N=12; Not yet recruiting; Sponsor: Bayer
Clinical • New P2 trial
1 to 15
Of
15
Go to page
1